Cardiac Safety Screening Services

Brochure Description

Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds.

  • Non-GLP hERG screening to eliminate cardiac risk liability.
  • Comprehensive in vitro proarrhythmia assay.
  • hiPSC-derived cardiomyocyte model for early cardiac derisking.
  • Evaluate the effect of compounds on action potentials recorded from hiPSC-derived cardiomyocytes using manual patch screening.
  • Chronic cardiotoxicity assay: hiPSC-derived cardiomyocytes to measure the cardiotoxic potential of test compounds.
  • High-quality, cost effective and rapid turnaround GLP testing against hERG.

Please contact us if you would like further information on our Cardiac Safety Screening Services.

Download
Recommended Publications
Latest Publications
Specialist Neuroscience Services

Highly specialised and tailored neuronal assays for pharmacological screening.

Ion Channel and HTS Services

Specialist ion channel screening to accelerate early-stage screening and lead optimisation.

View All
Secondary pharmacology publication recognised as ‘Most Impactful Publication of the Year’ by the Safety Pharmacology Society
Publication in support of refining the hERG testing strategy for silencing RNA (siRNA) receives ‘2024 Technology Innovation Publication Award’ from the Safety Pharmacology Society
View All
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram